Cargando…
Tenofovir use is associated with a decreased risk of hepatocellular carcinoma among men with HIV irrespective of coinfection status
BACKGROUND & AIMS: Tenofovir is recommended as part of the first-line antiretroviral therapy (ART) to treat people living with HIV (PLWH) with HBV coinfection. However, the effects of tenofovir-containing ART on hepatocellular carcinoma (HCC) risk among PLWH with/without chronic hepatitis virus...
Autores principales: | Lee, Mei-Hsuan, Wu, Ping-Feng, Chen, Tzu-I, Chan, Chi, Lin, Hsi-Hsun, Huang, Yi-Hsiang, Chen, Hsuan-Yu, Lin, Yi-Tsung, Chen, Chien-Jen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9852951/ https://www.ncbi.nlm.nih.gov/pubmed/36686591 http://dx.doi.org/10.1016/j.jhepr.2022.100634 |
Ejemplares similares
-
Week 96 Results of Switching from Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide among HIV/Hepatitis B Virus-Coinfected Patients
por: Huang, Yu-Shan, et al.
Publicado: (2023) -
Association of Hepatitis B and C Virus with the Risk of Coronary Artery Disease and Cerebrovascular Disease in Patients with Hepatocellular Carcinoma
por: Lu, Meng-Chuan, et al.
Publicado: (2023) -
Radiofrequency Ablation Is Superior to Ethanol Injection in Early-Stage Hepatocellular Carcinoma Irrespective of Tumor Size
por: Lin, Zhong-Zhe, et al.
Publicado: (2013) -
Tenofovir Hampers the Efficacy of Sorafenib in Prolonging Overall Survival in Hepatocellular Carcinoma
por: Liang, Kung-Hao, et al.
Publicado: (2021) -
Fifteen-Year Population Attributable Fractions and Causal Pies of Risk Factors for Newly Developed Hepatocellular Carcinomas in 11,801 Men in Taiwan
por: Liao, Shu-Fen, et al.
Publicado: (2012)